Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Affiliations

Comment

Stephan Moll. Ann Intern Med. 2020.

. 2020 Apr 7;172(7):510.

doi: 10.7326/L20-0053.

¹ University of North Carolina School of Medicine, Chapel Hill, North Carolina (S.M.).

No abstract available

Comment in

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Cortés-Hernández J. Cortés-Hernández J. Ann Intern Med. 2020 Sep 15;173(6):505-506. doi: 10.7326/L20-0054. Ann Intern Med. 2020. PMID: 32926827 No abstract available.

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J. Ordi-Ros J, et al. Ann Intern Med. 2019 Nov 19;171(10):685-694. doi: 10.7326/M19-0291. Epub 2019 Oct 15. Ann Intern Med. 2019. PMID: 31610549 Clinical Trial.
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Leong D, Wu PE. Leong D, et al. Ann Intern Med. 2020 Apr 7;172(7):509-510. doi: 10.7326/L20-0052. Ann Intern Med. 2020. PMID: 32252074 No abstract available.